These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 8123486)
1. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors. Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486 [TBL] [Abstract][Full Text] [Related]
2. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494 [TBL] [Abstract][Full Text] [Related]
3. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164 [TBL] [Abstract][Full Text] [Related]
4. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast]. Sánchez Salmón A; Argibay S; Arias JI; Ruibal A Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785 [TBL] [Abstract][Full Text] [Related]
5. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation]. Ruibal A; Arias JI; Resino C; Lapeña G; Schneider J; Tejerina A Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070 [TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors. Valerón PF; Chirino R; Vega V; Falcón O; Rivero JF; Torres S; León L; Fernández L; Pestano J; Díaz-Chico B; Díaz-Chico JC Int J Cancer; 1997 Apr; 74(2):175-9. PubMed ID: 9133451 [TBL] [Abstract][Full Text] [Related]
7. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay]. Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210 [TBL] [Abstract][Full Text] [Related]
8. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Hurlimann J; Gebhard S; Gomez F Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242 [TBL] [Abstract][Full Text] [Related]
9. Effect of steroid receptors, pS2 and cathepsin D on the outcome of elderly breast cancer patients: an exploratory investigation. Coradini D; Biganzoli E; Boracchi P; Bombardieri E; Seregni E; De Palo G; Martelli G; Di Fronzo G Int J Cancer; 1998 Aug; 79(4):305-11. PubMed ID: 9699519 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052 [TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677 [TBL] [Abstract][Full Text] [Related]
12. [Analysis of the cytosolic content of the pS2 protein in breast cancer]. Tamargo F; Vizoso F; Lamelas ML; Rodil A; Vérez P; Raigoso P; Mulero M; Vázquez J; Roiz C; Allende MT Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999 [TBL] [Abstract][Full Text] [Related]
13. Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer. Pujol P; Daurès JP; Brouillet JP; Maudelonde T; Rochefort H; Grenier J Br J Cancer; 1999 Feb; 79(5-6):909-14. PubMed ID: 10070889 [TBL] [Abstract][Full Text] [Related]
14. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985 [TBL] [Abstract][Full Text] [Related]
15. [Infiltrating ductal carcinomas of the breast in women over 60 years of age. Association with higher cellular proliferation and lower PS2, cell surface and cytosolic hyaluronic acid concentrations]. Ruibal A; Arias J; Del Río MC; Resino C; Tejerina A Rev Esp Med Nucl; 2001 Dec; 20(7):525-9. PubMed ID: 11709137 [TBL] [Abstract][Full Text] [Related]
16. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer. Racca S; Conti G; Pietribiasi F; Stramignoni D; Tampellini M; Valetto MR; Ghezzo F; Di Carlo F Int J Biol Markers; 1995; 10(2):87-93. PubMed ID: 7561244 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer. Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696 [TBL] [Abstract][Full Text] [Related]
18. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440 [TBL] [Abstract][Full Text] [Related]
19. Biphasic Scatchard plots of oestrogen receptors are associated with low pS2 levels in human breast cancers. Marsigliante S; Biscozzo L; Leo G; Storelli C Cancer Lett; 1999 Sep; 144(1):17-23. PubMed ID: 10503873 [TBL] [Abstract][Full Text] [Related]
20. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma]. Göhring UJ; Scharl A; Ahr A Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]